VIM-2–producingPseudomonas putida, Buenos Aires

Pseudomonas putida bacteremia in adult patients: five case reports and a review of the literature

“…Most reported cases of bacteremia with P. putida have been neonatal infections or outbreak infections due to transfusion of contaminated blood or fluid [6][7][8]. P. putida can acquire broad resistance to b-lactam antibiotics, and some isolates of this organism are capable of producing metallo-b-lactamases [9][10][11][12]. Despite this, there have been few reports about antimicrobial susceptibilities in bacteremia.…”

The Complete Nucleotide Sequence of the Carbapenem Resistance-Conferring Conjugative Plasmid pLD209 from a Pseudomonas putida Clinical Strain Reveals a Chimeric Design Formed by Modules Derived from Both Environmental and Clinical Bacteria

“…Recently, however, VIM-and IMP-like metallo-␤-lactamase (M␤L)-containing P. putida clinical strains displaying resistance to most ␤-lactams have been described and proposed to represent M␤L gene reservoirs (2)(3)(4)(5). This poses a serious challenge to antimicrobial therapy due to the potential role of this environmental species in M␤L gene dissemination among human pathogens such as Pseudomonas aeruginosa (5,6).…”

First Report of an Extensively Drug-Resistant VIM-2 Metallo-β-Lactamase-Producing Brevundimonas diminuta Clinical Isolate

“…Since the first description of VIM-2 in southern France (Marseilles) in a P. aeruginosa isolate from a blood culture of a neutropenic patient in 1996 (11), this enzyme has been detected in many other species of nonfermenting Gram-negative rods, such as Pseudomonas putida (1,14), Pseudomonas fluorescens (14), Pseudomonas stutzeri (14), Pseudomonas pseudoalcaligenes (12), Pseudomonas fulva (2), Achromobacter xylosoxidans (14), and Acinetobacter baumannii (14).…”